Free Trial

Creo Medical Group (CREO) Competitors

Creo Medical Group logo
GBX 18 +0.25 (+1.41%)
(As of 11/8/2024 ET)

CREO vs. EKF, NCYT, IUG, POLX, BELL, IHC, AVO, RUA, MHC, and SUN

Should you be buying Creo Medical Group stock or one of its competitors? The main competitors of Creo Medical Group include EKF Diagnostics (EKF), Novacyt (NCYT), Intelligent Ultrasound Group (IUG), Polarean Imaging (POLX), Belluscura (BELL), Inspiration Healthcare Group (IHC), Advanced Oncotherapy (AVO), RUA Life Sciences (RUA), MyHealthChecked (MHC), and Surgical Innovations Group (SUN). These companies are all part of the "medical devices" industry.

Creo Medical Group vs.

Creo Medical Group (LON:CREO) and EKF Diagnostics (LON:EKF) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their analyst recommendations, profitability, risk, media sentiment, community ranking, valuation, earnings, institutional ownership and dividends.

56.1% of Creo Medical Group shares are owned by institutional investors. Comparatively, 70.3% of EKF Diagnostics shares are owned by institutional investors. 22.4% of Creo Medical Group shares are owned by company insiders. Comparatively, 5.2% of EKF Diagnostics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

EKF Diagnostics has a net margin of 9.37% compared to Creo Medical Group's net margin of -73.93%. EKF Diagnostics' return on equity of 7.58% beat Creo Medical Group's return on equity.

Company Net Margins Return on Equity Return on Assets
Creo Medical Group-73.93% -38.49% -20.09%
EKF Diagnostics 9.37%7.58%5.27%

In the previous week, Creo Medical Group had 1 more articles in the media than EKF Diagnostics. MarketBeat recorded 1 mentions for Creo Medical Group and 0 mentions for EKF Diagnostics. EKF Diagnostics' average media sentiment score of 0.00 beat Creo Medical Group's score of -1.05 indicating that EKF Diagnostics is being referred to more favorably in the news media.

Company Overall Sentiment
Creo Medical Group Negative
EKF Diagnostics Neutral

EKF Diagnostics has higher revenue and earnings than Creo Medical Group. Creo Medical Group is trading at a lower price-to-earnings ratio than EKF Diagnostics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Creo Medical Group£30.30M2.15-£22.40M-£0.06-300.00
EKF Diagnostics£50.95M2.46£4.78M£0.012,765.00

EKF Diagnostics received 221 more outperform votes than Creo Medical Group when rated by MarketBeat users. Likewise, 76.76% of users gave EKF Diagnostics an outperform vote while only 67.52% of users gave Creo Medical Group an outperform vote.

CompanyUnderperformOutperform
Creo Medical GroupOutperform Votes
106
67.52%
Underperform Votes
51
32.48%
EKF DiagnosticsOutperform Votes
327
76.76%
Underperform Votes
99
23.24%

Creo Medical Group has a beta of 0.86, indicating that its stock price is 14% less volatile than the S&P 500. Comparatively, EKF Diagnostics has a beta of 0.57, indicating that its stock price is 43% less volatile than the S&P 500.

Summary

EKF Diagnostics beats Creo Medical Group on 12 of the 15 factors compared between the two stocks.

Get Creo Medical Group News Delivered to You Automatically

Sign up to receive the latest news and ratings for CREO and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

CREO vs. The Competition

MetricCreo Medical GroupMedical Devices IndustryMedical SectorLON Exchange
Market Cap£65.12M£2.11B£5.39B£1.58B
Dividend YieldN/A2.49%4.61%11.03%
P/E Ratio-300.00210.54111.961,668.58
Price / Sales2.15205.811,289.62232,151.23
Price / Cash2.4316.0539.1436.61
Price / Book1.383.416.043.09
Net Income-£22.40M£70.94M£118.88M£142.59M
7 Day Performance-7.82%-0.11%5.08%20.90%
1 Month Performance-19.46%-1.59%11.07%18.11%
1 Year Performance-46.67%23.35%45.44%30.54%

Creo Medical Group Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
CREO
Creo Medical Group
N/AGBX 18
+1.4%
N/A-48.6%£65.12M£30.30M-300.00279Negative News
High Trading Volume
EKF
EKF Diagnostics
N/AGBX 26.80
-1.8%
N/A-2.1%£121.60M£50.95M2,680.00356
NCYT
Novacyt
N/AGBX 54.40
-0.4%
N/A-5.0%£38.42M£18.56M-104.62120
IUG
Intelligent Ultrasound Group
N/AGBX 11.15
-3.0%
N/A+14.0%£36.47M£9.88M-1,115.0065Gap Up
POLX
Polarean Imaging
N/AGBX 1.59
+3.9%
N/A-79.2%£19.18M£1.87M-79.2528
BELL
Belluscura
N/AGBX 10.68
+1.7%
N/A-62.2%£17.99M£1.80M-106.8024
IHC
Inspiration Healthcare Group
N/AGBX 17.25
-1.4%
N/A-59.3%£15.47M£34.30M-123.21224Gap Up
AVO
Advanced Oncotherapy
N/AGBX 1.75
-9.1%
N/A+0.0%£9.50MN/A-25.003,900Gap Down
RUA
RUA Life Sciences
N/AGBX 11.10
-3.5%
N/A-12.7%£6.89M£2.19M-277.5048
MHC
MyHealthChecked
N/AGBX 12.23
-4.1%
N/A+22.0%£6.36M£9.39M-611.2516News Coverage
Gap Down
SUN
Surgical Innovations Group
N/AGBX 0.50
-8.7%
N/A-39.7%£4.68M£12.54M-21.1180Gap Down

Related Companies and Tools


This page (LON:CREO) was last updated on 11/9/2024 by MarketBeat.com Staff
From Our Partners